文献速递心力衰竭与心肌病

PDE4B心脏过表达减弱β肾上腺素能反应并改善心衰不良重构

Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
PubMed 文献 · Circulation · 2020-04-08

研究测量了人心衰组织中PDE4B表达,并构建了心肌细胞特异性过表达PDE4B的两种转基因小鼠品系及AAV9-PDE4B载体,以异丙肾上腺素输注或主动脉缩窄诱导心衰。结果显示人心衰心脏PDE4B蛋白降低;适度增加PDE4B可减弱β肾上腺素能反应而不影响基础功能,并防止收缩功能障碍、凋亡和纤维化,提示PDE4B心脏基因治疗可能是心衰治疗新途径。

要点

  • 人心衰心脏中PDE4B蛋白表达降低。
  • 适度增加PDE4B可减弱β肾上腺素能反应并保护心脏免受不良重构。
  • AAV9介导的PDE4B基因转移在两种心衰模型中显示保护作用。

核心结论

  • 适度增加PDE4B具有心脏保护作用,PDE4B心脏基因治疗可能成为治疗心衰的新方法。

研究设计与样本

  • 测量人心衰心脏组织中PDE4B表达。
  • 构建2种心肌细胞特异性过表达PDE4B的转基因小鼠品系(TG15、TG50)。
  • 使用AAV9编码PDE4B(每只小鼠10^12病毒颗粒)注射小鼠。
  • 通过超声心动图、心电图和Langendorff灌注心脏评估心肌结构与功能。
  • 用FRET监测cAMP与PKA活性,全细胞膜片钳测L型Ca2+电流,Ionoptix系统测心肌细胞缩短与Ca2+瞬变。

主要发现

  • 人心衰心脏中PDE4B蛋白降低。
  • TG15小鼠心脏cAMP-PDE活性增加约15倍,cAMP含量与缩短分数降低约30%,伴轻度心脏肥厚且随年龄消退。
  • TG15小鼠基础离体心肌功能不变,但β肾上腺素能受体刺激的正性肌力作用、cAMP、PKA、L型Ca2+电流、Ca2+瞬变和细胞收缩均减弱。
  • TG15小鼠耐力与预期寿命正常,并免受慢性异丙肾上腺素诱导的收缩功能障碍、肥厚、肺淤血和纤维化。
  • TG50小鼠PDE4B过表达更高,心脏cAMP-PDE活性增加约50倍,缩短分数降低约50%,出现肥厚、扩张和过早死亡。

临床怎么用

  • PDE4B适度增加可能作为心衰基因治疗策略,但需把握表达水平,避免过度过表达导致心功能恶化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cyclic AMP (adenosine monophosphate; cAMP)-hydrolyzing protein PDE4B (phosphodiesterase 4B) is a key negative regulator of cardiac β-adrenergic receptor stimulation. PDE4B deficiency leads to abnormal Ca2+ handling and PDE4B is decreased in pressure overload hypertrophy, suggesting that increasing PDE4B in the heart is beneficial in heart failure. METHODS: We measured PDE4B expression in human cardiac tissues and developed 2 transgenic mouse lines with cardiomyocyte-specific overexpression of PDE4B and an adeno-associated virus serotype 9 encoding PDE4B. Myocardial structure and function were evaluated by echocardiography, ECG, and in Langendorff-perfused hearts. Also, cAMP and PKA (cAMP dependent protein kinase) activity were monitored by Förster resonance energy transfer, L-type Ca2+ current by whole-cell patch-clamp, and cardiomyocyte shortening and Ca2+ transients with an Ionoptix system. Heart failure was induced by 2 weeks infusion of isoproterenol or transverse aortic constriction. Cardiac remodeling was evaluated by serial echocardiography, morphometric analysis, and histology. RESULTS: PDE4B protein was decreased in human failing hearts. The first PDE4B-transgenic mouse line (TG15) had a ≈15-fold increase in cardiac cAMP-PDE activity and a ≈30% decrease in cAMP content and fractional shortening associated with a mild cardiac hypertrophy that resorbed with age. Basal ex vivo myocardial function was unchanged, but β-adrenergic receptor stimulation of cardiac inotropy, cAMP, PKA, L-type Ca2+ current, Ca2+ transients, and cell contraction were blunted. Endurance capacity and life expectancy were normal. Moreover, these mice were protected from systolic dysfunction, hypertrophy, lung congestion, and fibrosis induced by chronic isoproterenol treatment. In the second PDE4B-transgenic mouse line (TG50), markedly higher PDE4B overexpression, resulting in a ≈50-fold increase in cardiac cAMP-PDE activity caused a ≈50% decrease in fractional shortening, hypertrophy, dilatation, and premature death. In contrast, mice injected with adeno-associated virus serotype 9 encoding PDE4B (1012 viral particles/mouse) had a ≈50% increase in cardiac cAMP-PDE activity, which did not modify basal cardiac function but efficiently prevented systolic dysfunction, apoptosis, and fibrosis, while attenuating hypertrophy induced by chronic isoproterenol infusion. Similarly, adeno-associated virus serotype 9 encoding PDE4B slowed contractile deterioration, attenuated hypertrophy and lung congestion, and prevented apoptosis and fibrotic remodeling in transverse aortic constriction. CONCLUSIONS: Our results indicate that a moderate increase in PDE4B is cardioprotective and suggest that cardiac gene therapy with PDE4B might constitute a new promising approach to treat heart failure.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Karam S, Margaria JP, Bourcier A, et al. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure. Circulation. 2020. PMID: 32264695. doi:10.1161/CIRCULATIONAHA.119.042573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。